argenx SE (NASDAQ:ARGX) Shares Bought by ANTIPODES PARTNERS Ltd

ANTIPODES PARTNERS Ltd grew its holdings in shares of argenx SE (NASDAQ:ARGX) by 114.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 116 shares of the company’s stock after acquiring an additional 62 shares during the period. ANTIPODES PARTNERS Ltd’s holdings in argenx were worth $71,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Steward Partners Investment Advisory LLC boosted its stake in argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC grew its stake in argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares in the last quarter. Finally, Choreo LLC increased its holdings in argenx by 4.4% in the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after buying an additional 23 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

ARGX stock opened at $591.45 on Thursday. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The stock’s fifty day moving average is $639.78 and its two-hundred day moving average is $595.30. The stock has a market capitalization of $35.94 billion, a price-to-earnings ratio of -672.10 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. As a group, analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wedbush reaffirmed an “outperform” rating and set a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. Wells Fargo & Company raised their price objective on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Citigroup restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. William Blair restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Finally, HC Wainwright raised their price objective on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.